Sexcord/ stromal ovarian tumors natural history, complications and prognosis: Difference between revisions
Line 36: | Line 36: | ||
*Most sexcord-stromal ovarian tumors present at a low tumor stage and also prognosis in these patients is excellent | *Most sexcord-stromal ovarian tumors present at a low tumor stage and also prognosis in these patients is excellent | ||
*Patients with juvinile granulosa cell tumors(JGCT) and sertoli-Leydig cell tumors (SLCTs) show greater mitotic activity than all other histologic types | *Patients with juvinile granulosa cell tumors(JGCT) and sertoli-Leydig cell tumors (SLCTs) show greater mitotic activity than all other histologic types | ||
*The presence of greater mitotic activity is associated with a particularly poor prognosis among patients with juvinile granulosa cell tumors(JGCT) and sertoli-Leydig cell tumors (SLCTs) | |||
*The presence of | |||
*[Subtype of disease/malignancy] is associated with the most favorable prognosis. | *[Subtype of disease/malignancy] is associated with the most favorable prognosis. | ||
*The prognosis varies with the subtypes of tumor<ref name="pmid24416992">{{cite journal |vauthors=Elashry R, Hemida R, Goda H, Abdel-Hady el-S |title=Prognostic factors of germ cell and sex cord-stromal ovarian tumors in pediatric age: 5 years experience |journal=J. Exp. Ther. Oncol. |volume=10 |issue=3 |pages=181–7 |date=2013 |pmid=24416992 |doi= |url=}}</ref> | *The prognosis varies with the subtypes of tumor<ref name="pmid24416992">{{cite journal |vauthors=Elashry R, Hemida R, Goda H, Abdel-Hady el-S |title=Prognostic factors of germ cell and sex cord-stromal ovarian tumors in pediatric age: 5 years experience |journal=J. Exp. Ther. Oncol. |volume=10 |issue=3 |pages=181–7 |date=2013 |pmid=24416992 |doi= |url=}}</ref> | ||
*Sertoli-Leydig cell tumors have a 70 to 90 percent five-year survival overall and is mainly related to the stage and degree of histologic differentiation. | *Sertoli-Leydig cell tumors have a 70 to 90 percent five-year survival overall and is mainly related to the stage and degree of histologic differentiation. | ||
*The two important predictors for improved survival in patients with ovarian sex cord stromal tumors are young age and early-stage disease | |||
==References== | ==References== |
Revision as of 17:22, 9 April 2019
Sexcord/ stromal ovarian tumors Microchapters |
Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Sexcord/ stromal ovarian tumors natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors natural history, complications and prognosis |
FDA on Sexcord/ stromal ovarian tumors natural history, complications and prognosis |
CDC on Sexcord/ stromal ovarian tumors natural history, complications and prognosis |
Sexcord/ stromal ovarian tumors natural history, complications and prognosis in the news |
Blogs on Sexcord/ stromal ovarian tumors natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of sexcord/ stromal ovarian tumors usually develop in the second/ third/ fourth decade of life, and start with symptoms such as:
- Adnexal mass
- Abdominal & pelvic symptoms
- Bloating
- Urinary urgency or frequency
- Dysphagia(difficulty eating) or feeling full quickly
- Pelvic or abdominal pain
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of [disease name] include:
- [Complication 1]
- [Complication 2]
- [Complication 3]
Prognosis
- Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as excellent[1][2][3][4]
- Most sexcord-stromal ovarian tumors present at a low tumor stage and also prognosis in these patients is excellent
- Patients with juvinile granulosa cell tumors(JGCT) and sertoli-Leydig cell tumors (SLCTs) show greater mitotic activity than all other histologic types
- The presence of greater mitotic activity is associated with a particularly poor prognosis among patients with juvinile granulosa cell tumors(JGCT) and sertoli-Leydig cell tumors (SLCTs)
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the subtypes of tumor[2]
- Sertoli-Leydig cell tumors have a 70 to 90 percent five-year survival overall and is mainly related to the stage and degree of histologic differentiation.
- The two important predictors for improved survival in patients with ovarian sex cord stromal tumors are young age and early-stage disease
References
- ↑ Schneider DT, Calaminus G, Harms D, Göbel U (June 2005). "Ovarian sex cord-stromal tumors in children and adolescents". J Reprod Med. 50 (6): 439–46. PMID 16050568.
- ↑ 2.0 2.1 Elashry R, Hemida R, Goda H, Abdel-Hady e (2013). "Prognostic factors of germ cell and sex cord-stromal ovarian tumors in pediatric age: 5 years experience". J. Exp. Ther. Oncol. 10 (3): 181–7. PMID 24416992. Vancouver style error: initials (help)
- ↑ Zanagnolo V, Pasinetti B, Sartori E (2004). "Clinical review of 63 cases of sex cord stromal tumors". Eur. J. Gynaecol. Oncol. 25 (4): 431–8. PMID 15285297.
- ↑ Zhang, Mallory; Cheung, Michael K.; Shin, Jacob Y.; Kapp, Daniel S.; Husain, Amreen; Teng, Nelson N.; Berek, Jonathan S.; Osann, Kathryn; Chan, John K. (2007). "Prognostic factors responsible for survival in sex cord stromal tumors of the ovary—An analysis of 376 women". Gynecologic Oncology. 104 (2): 396–400. doi:10.1016/j.ygyno.2006.08.032. ISSN 0090-8258.